IP Library Granted Patent US 7,316,925
Granted Patent B2
US 7,316,925 · App. 10/619,939 · Granted Jan 8, 2008

Codon optimized synthetic plasmids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,316,925
App. No.
10/619,939
Granted
Jan 8, 2008
Kind
B2
Abstract

One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.

Claims (10)

1. A synthetic mammalian expression plasmid for plasmid mediated gene supplementation in a species comprising:

(a) a synthetic or eukaryotic promoter comprising SEQ ID NO: 15;

(b) a codon-optimized eukaryotic therapeutic gene sequence comprising SEQ ID NO: 7;

(c) a polyadenylation signal;

(d) a selectable marker gene sequence;

(e) a ribosomal binding site;

(f) a promoter for the selectable marker gene sequence; and

(g) an origin of replication;

wherein the synthetic or eukaryotic promoter, the codon-optimized-eukaryotic therapeutic gene sequence, and the polyadenylation signal comprise therapeutic elements of the synthetic mammalian expression plasmid; the therapeutic elements are operatively linked and located in a first operatively-linked arrangement; the selectable marker gene promoter, the ribosomal binding site, the selectable marker gene sequence, and the origin of replication comprise replication elements of the synthetic mammalian expression plasmid; the replication elements are operatively linked and located in a second-operatively-linked arrangement; and the first-operatively linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the synthetic mammalian expression plasmid.

2. A synthetic mammalian expression plasmid comprising SEQ ID NO: 19.

Assignments (2)
MERGER Recorded Feb 2, 2021
From: VGX PHARMACEUTICALS, LLC
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 055114/0843 →
MERGER AND CHANGE OF NAME Recorded Dec 21, 2020
From: VGX PHARMACEUTICALS, INC.; INOVIO ACQUISITION, LLC
To: VGX PHARMACEUTICALS, LLC
Reel/Frame 054704/0830 →